These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 35676620)

  • 21. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
    Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
    J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
    Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
    Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
    Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
    Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
    Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
    J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M
    Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
    J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
    Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
    J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.
    Peyrin-Biroulet L; Danese S; Argollo M; Pouillon L; Peppas S; Gonzalez-Lorenzo M; Lytras T; Bonovas S
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):838-846.e2. PubMed ID: 29935327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
    Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
    Olbjørn C; Rove JB; Jahnsen J
    Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Pugliese D; Privitera G; Crispino F; Mezzina N; Castiglione F; Fiorino G; Laterza L; Viola A; Bertani L; Caprioli F; Cappello M; Barberio B; Ricci C; Balestrieri P; Daperno M; Pluchino D; Rizzello F; Scribano ML; Sablich R; Pastorelli L; Manguso F; Variola A; Di Sario A; Grossi L; Armuzzi A;
    Aliment Pharmacol Ther; 2022 Jul; 56(1):95-109. PubMed ID: 35876062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment.
    Bouhnik Y; Atreya R; Casey D; Górecki M; Baik D; Yoon SW; Kwon TS; Jang M
    Inflamm Bowel Dis; 2023 Jun; 29(6):898-913. PubMed ID: 35942647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.